What is the meropenem intravenous dose in milliliters for a 2.5‑month‑old infant weighing 2.67 kg with severe anemia and congenital heart disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meropenem Dosing for a 2.5-Month-Old Infant Weighing 2.67 kg

For this 2.67 kg, 2.5-month-old infant, administer meropenem 20 mg/kg every 8 hours (approximately 53 mg per dose) as a 30-minute intravenous infusion.

Dose Calculation Algorithm

The precise dose depends on gestational age at birth and current postnatal age 1, 2:

If Term Infant (≥32 weeks gestational age):

  • Postnatal age ≥14 days (which applies to a 2.5-month-old): 30 mg/kg every 8 hours 1
  • Calculated dose: 30 mg/kg × 2.67 kg = 80 mg per dose every 8 hours 1

If Premature Infant (<32 weeks gestational age):

  • Postnatal age ≥14 days: 20 mg/kg every 8 hours 1
  • Calculated dose: 20 mg/kg × 2.67 kg = 53 mg per dose every 8 hours 1

Volume Calculation for Administration

Meropenem is typically reconstituted to standard concentrations 2:

  • If using 50 mg/mL concentration:

    • For 80 mg dose (term infant): 1.6 mL per dose
    • For 53 mg dose (preterm infant): 1.06 mL per dose
  • If using 20 mg/mL concentration:

    • For 80 mg dose (term infant): 4 mL per dose
    • For 53 mg dose (preterm infant): 2.65 mL per dose

Administration Guidelines

  • Infusion time: Administer over 30 minutes as an intravenous infusion 2
  • Frequency: Every 8 hours 1, 2
  • Maximum dose: Not applicable at this weight, as the calculated dose is well below the 2-gram maximum 2

Critical Considerations for This Patient

Severe Anemia and CHD Context:

  • The presence of severe anemia and congenital heart disease does not alter the standard meropenem dosing regimen 2
  • However, monitor hemoglobin closely, as diagnostic blood draws for therapeutic drug monitoring may worsen anemia in this vulnerable population 3
  • Consider blood conservation strategies given the underlying severe anemia 4

Hematologic Monitoring:

  • Monitor complete blood counts closely during meropenem therapy, as pancytopenia (including thrombocytopenia, anemia, and neutropenia) has been reported in preterm neonates receiving meropenem 5
  • This is particularly important given the pre-existing severe anemia 5
  • If pancytopenia develops, counts typically improve within 4-7 days after discontinuation 5

Common Pitfalls to Avoid

  • Do not underdose based on the infant's low weight – use the full mg/kg dose as recommended 1, 2
  • Do not use the lower 20 mg/kg dose if the infant is term – term infants ≥14 days old require 30 mg/kg every 8 hours 1
  • Do not administer as a bolus injection in infants this young – always use 30-minute infusion 2
  • Do not assume the anemia or CHD require dose adjustment – these conditions do not alter meropenem pharmacokinetics requiring dose modification 2

References

Guideline

Meropenem Dosing Recommendations for Neonates and Young Infants

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Recommendations on RBC Transfusion in Infants and Children With Acquired and Congenital Heart Disease From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.